title: [The treatment effects analysis of 164 patients with sudden sensorineural hearing loss].
abstract: OBJECTIVE
  To explore the effective treatment of sudden sensorineural hearing loss and factors affecting its prognosis.
  
  
  METHODS
  The clinical data and follow-up results of 164 patients with sudden sensorineural hearing loss were analyzed retrospectively. All the 164 patients were given intravenous vasodilator, neurotrophic drugs treatment, oral prednisone treatment, and intratympanic dexamethasone injection. All patients were divided into low frequency hearing loss type,intermediate frequency hearing loss, high frequency hearing loss, all frequency hearing loss and total deafness group. Pure tone hearing threshold test were performed before and 3 months after treatment. All patients and different groups were compared before and after treatment damage frequency of average air conduction and various frequency air conduction hearing. Analysis of gender, age, process and hearing curve type, frequency hearing of impaired before treatment, the symptoms with or without vertigo.
  
  
  RESULTS
  All the patients' hearing improved after treatment. The treatment efficiency was 46.3%, and low frequency hearing improvements were better than the high frequency hearing. Including age, process, frequency hearing of impaired before treatment, with or without vertigo isindependent factors influencing its prognosis.
  
  
  CONCLUSIONS
  Based on the regular treatment,oral and intratympanic injection glucocorticoid therapy are safe and effective for sudden hearing loss,The prognosis and age, course, impaired hearing before curve type, treatment frequency hearing level is closely related, with or without vertigo.
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
authors.forename: Wen
authors.initials: W
authors.lastname: Xie
authors.forename: Hong
authors.initials: H
authors.lastname: Xu
authors.forename: Yuehui
authors.initials: Y
authors.lastname: Liu
mesh_terms: D000284:Administration, Oral; D001301:Audiometry, Pure-Tone; D003638:Deafness / Q000175:diagnosis / Q000188:drug therapy; D003907:Dexamethasone / Q000627:therapeutic use*; D006316:Hearing Loss, High-Frequency / Q000175:diagnosis / Q000188:drug therapy; D006319:Hearing Loss, Sensorineural / Q000175:diagnosis / Q000188:drug therapy; D003639:Hearing Loss, Sudden / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D011241:Prednisone / Q000627:therapeutic use*; D011379:Prognosis; D012189:Retrospective Studies; D016896:Treatment Outcome; D014432:Tympanic Membrane; D014665:Vasodilator Agents; D014717:Vertigo / Q000150:complications
chemical_list: D014665:Vasodilator Agents; D003907:Dexamethasone; D011241:Prednisone